The FDA approves the first AI tool to predict the risk of breast cancer

The Food and Drug Administration (FDA) of the United States has approved the first artificial intelligence tool (AI) to predict the risk of breast cancer.

The authorization was confirmed by the digital company Health Tech Clairity, the developer of Clairity Breast, a new images -based predicted platform designed to predict the risk of five -year breast cancer from a routine screening mammogram.

In a press release, Clairity shared its plans to launch the AI ​​platform through health systems until 2025.

AI detects ovary cancer better than human experts in a new study

According to Clairity, risk assessment models for breast cancer are based on family age and history.

However, about 85% of cases occur in women who have no family history of breast cancer, probably derived from genetic mutations that occur due to aging, according to health agencies.

Traditional risk models have also been based on predominantly European Caucasian women, which Clairity said it has not been “widespread” for different backgrounds.

The AI ​​tool analyzes subtle images of a screening mammogram that correlates with the risk of breast cancer, then generates a “validated risk score of five years” and pounds it to healthcare suppliers, said the company.

AI detects the woman’s breast cancer after routine screening lost it: “deeply grateful”

Connie Lehman, founder of Clairity and breast images of General Mass Brigham, emphasized the importance of mammograms in the early detection of cancer.

“Now, the advances in the AI ​​and computer vision can discover hidden clues in mammograms, invisible to the human eye, to help predict the future risk,” he said in a statement.

“By delivering valued and equitable risk assessments, we can help expand access to the early detection and prevention of life for women everywhere.”

Click here to get the Fox News app

Dr. Robert A. Smith, a Senior Vice President of the American Cancer Cancer Cancer Science, also said a statement that personalized screening based on risk is “critical of improving breast cancer results and AI tools offer us the best opportunity to fulfill this potential.”

“This is the wave of the future. The AI ​​will be part of the equation, but it will not be in charge.”

“Clairity FDA authorization is a turning point for more women to access scientific advances in Ai -based cancer risk prediction,” wrote Larry Norton, founding scientific director of the Breast Cancer Cancer Foundation, wrote in another statement.

“Breast cancer increases, especially among younger women, but most risk models often lose those who will develop the disease,” he said. “We can now ensure that more women are properly careful at the right time.”

More than 2.3 million women are diagnosed with a worldwide breast cancer each year, including more than 370,000 in the United States, despite the “decades of progress”, according to the Breast Cancer Research Foundation.

Cases have been especially increasing among younger women under the age of 50.

Click here to register -you are in our health newsletter

In an appearance on Tuesday in “America’s Newsroom”, Fox News Senior Medical Analyst, Dr. Marc Siegel, called the “deep” Clairity development.

“Just look at a mammogram … sometimes [radiologists] We will see things that are not clear, they must follow them over time, “he said.” II improves focus and predictive that is, [shown] Very dramatically in studies. “

Siegel confirmed that radiologists from all over the country are often supported by the AI ​​for the detection of cancer, especially in areas of the “undervalued” country in terms of health.

For more health items, visit www.foxnews.com/health

“In areas where you trust radiologists without special training, this is even more important,” he said.

“This is the wave of the future. The AI ​​will be part of the equation, but it will not be in charge.”